Endurant Capital Management LP Nektar Therapeutics Transaction History

Endurant Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $367,034 - $541,071	-7,900 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $365,375 - $825,155	7,900 New	7,900 $386,000
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $2.52 Million - $6.61 Million	-109,300 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $1.94 Million - $2.62 Million	109,300	109,300 $2.62 Million

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.